We have modified the criteria for type II LCNEC classification, which not only depended on the alteration status of the TP53 and RB1 genes, but also included two molecular features commonly reported in SCLC rather than NSCLC: MYC family amplifications and NOTCH family mutations. This evidence concerns the gene TP53 and large cell neuroendocrine carcinoma.